Intrinsic value of T2 Biosystems - TTOO

Previous Close

$4.70

  Intrinsic Value

$0.01

stock screener

  Rating & Target

str. sell

-100%

Previous close

$4.70

 
Intrinsic value

$0.01

 
Up/down potential

-100%

 
Rating

str. sell

We calculate the intrinsic value of TTOO stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 0001), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 0.2

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2
   3
   4
   5
   6
   7
   8
   9
   10
   11
   12
   13
   14
   15
   16
   17
   18
   19
   20
   21
   22
   23
   24
   25
   26
   27
   28
   29
   30
   31

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  60.00
  54.50
  49.55
  45.10
  41.09
  37.48
  34.23
  31.31
  28.68
  26.31
  24.18
  22.26
  20.53
  18.98
  17.58
  16.32
  15.19
  14.17
  13.26
  12.43
  11.69
  11.02
  10.42
  9.87
  9.39
  8.95
  8.55
  8.20
  7.88
  7.59
Revenue, $m
  7
  12
  17
  25
  35
  49
  65
  86
  110
  139
  173
  211
  254
  303
  356
  414
  477
  545
  617
  693
  775
  860
  949
  1,043
  1,141
  1,243
  1,350
  1,460
  1,575
  1,695
Variable operating expenses, $m
  28
  44
  66
  95
  134
  184
  248
  325
  418
  528
  656
  802
  967
  1,151
  1,353
  1,574
  1,813
  2,070
  2,344
  2,635
  2,943
  3,268
  3,608
  3,964
  4,336
  4,724
  5,128
  5,549
  5,986
  6,440
Fixed operating expenses, $m
  41
  42
  43
  44
  45
  46
  47
  48
  49
  50
  51
  52
  53
  54
  55
  57
  58
  59
  60
  62
  63
  65
  66
  67
  69
  70
  72
  74
  75
  77
Total operating expenses, $m
  69
  86
  109
  139
  179
  230
  295
  373
  467
  578
  707
  854
  1,020
  1,205
  1,408
  1,631
  1,871
  2,129
  2,404
  2,697
  3,006
  3,333
  3,674
  4,031
  4,405
  4,794
  5,200
  5,623
  6,061
  6,517
Operating income, $m
  -62
  -74
  -91
  -114
  -143
  -182
  -229
  -287
  -357
  -439
  -534
  -643
  -766
  -902
  -1,052
  -1,216
  -1,394
  -1,584
  -1,788
  -2,004
  -2,232
  -2,472
  -2,724
  -2,988
  -3,264
  -3,552
  -3,851
  -4,162
  -4,486
  -4,822
EBITDA, $m
  -58
  -69
  -83
  -102
  -127
  -159
  -198
  -247
  -305
  -373
  -453
  -543
  -645
  -759
  -884
  -1,021
  -1,168
  -1,327
  -1,496
  -1,676
  -1,866
  -2,066
  -2,276
  -2,496
  -2,725
  -2,965
  -3,214
  -3,473
  -3,742
  -4,022
Interest expense (income), $m
  3
  9
  11
  15
  20
  27
  37
  49
  65
  84
  107
  133
  165
  201
  241
  286
  335
  389
  448
  511
  578
  649
  725
  804
  887
  974
  1,066
  1,161
  1,259
  1,362
  1,469
Earnings before tax, $m
  -71
  -85
  -106
  -134
  -171
  -218
  -278
  -352
  -441
  -546
  -668
  -808
  -966
  -1,143
  -1,338
  -1,551
  -1,783
  -2,032
  -2,298
  -2,581
  -2,881
  -3,197
  -3,528
  -3,876
  -4,239
  -4,617
  -5,011
  -5,422
  -5,848
  -6,292
Tax expense, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  -71
  -85
  -106
  -134
  -171
  -218
  -278
  -352
  -441
  -546
  -668
  -808
  -966
  -1,143
  -1,338
  -1,551
  -1,783
  -2,032
  -2,298
  -2,581
  -2,881
  -3,197
  -3,528
  -3,876
  -4,239
  -4,617
  -5,011
  -5,422
  -5,848
  -6,292

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  36
  55
  83
  120
  169
  232
  312
  409
  527
  665
  826
  1,010
  1,218
  1,449
  1,703
  1,981
  2,282
  2,606
  2,951
  3,318
  3,706
  4,114
  4,543
  4,991
  5,460
  5,949
  6,457
  6,987
  7,537
  8,109
Adjusted assets (=assets-cash), $m
  36
  55
  83
  120
  169
  232
  312
  409
  527
  665
  826
  1,010
  1,218
  1,449
  1,703
  1,981
  2,282
  2,606
  2,951
  3,318
  3,706
  4,114
  4,543
  4,991
  5,460
  5,949
  6,457
  6,987
  7,537
  8,109
Revenue / Adjusted assets
  0.194
  0.218
  0.205
  0.208
  0.207
  0.211
  0.208
  0.210
  0.209
  0.209
  0.209
  0.209
  0.209
  0.209
  0.209
  0.209
  0.209
  0.209
  0.209
  0.209
  0.209
  0.209
  0.209
  0.209
  0.209
  0.209
  0.209
  0.209
  0.209
  0.209
Average production assets, $m
  18
  27
  41
  59
  83
  115
  154
  202
  260
  328
  408
  498
  601
  715
  840
  977
  1,126
  1,285
  1,456
  1,637
  1,828
  2,029
  2,241
  2,462
  2,693
  2,934
  3,185
  3,446
  3,718
  4,000
Working capital, $m
  -13
  -20
  -30
  -44
  -62
  -86
  -115
  -151
  -194
  -245
  -305
  -373
  -449
  -534
  -628
  -731
  -842
  -961
  -1,089
  -1,224
  -1,367
  -1,518
  -1,676
  -1,841
  -2,014
  -2,194
  -2,382
  -2,577
  -2,780
  -2,991
Total debt, $m
  51
  69
  93
  127
  171
  228
  300
  388
  493
  618
  763
  928
  1,115
  1,323
  1,552
  1,802
  2,073
  2,364
  2,675
  3,006
  3,355
  3,722
  4,108
  4,511
  4,933
  5,373
  5,831
  6,307
  6,803
  7,318
Total liabilities, $m
  32
  50
  74
  108
  152
  209
  281
  368
  474
  599
  744
  909
  1,096
  1,304
  1,533
  1,783
  2,054
  2,345
  2,656
  2,986
  3,335
  3,703
  4,089
  4,492
  4,914
  5,354
  5,812
  6,288
  6,783
  7,298
Total equity, $m
  4
  6
  8
  12
  17
  23
  31
  41
  53
  67
  83
  101
  122
  145
  170
  198
  228
  261
  295
  332
  371
  411
  454
  499
  546
  595
  646
  699
  754
  811
Total liabilities and equity, $m
  36
  56
  82
  120
  169
  232
  312
  409
  527
  666
  827
  1,010
  1,218
  1,449
  1,703
  1,981
  2,282
  2,606
  2,951
  3,318
  3,706
  4,114
  4,543
  4,991
  5,460
  5,949
  6,458
  6,987
  7,537
  8,109
Debt-to-equity ratio
  14.360
  12.470
  11.320
  10.600
  10.130
  9.820
  9.610
  9.470
  9.360
  9.290
  9.230
  9.190
  9.160
  9.130
  9.110
  9.100
  9.080
  9.070
  9.060
  9.060
  9.050
  9.050
  9.040
  9.040
  9.040
  9.030
  9.030
  9.030
  9.030
  9.020
Adjusted equity ratio
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -71
  -85
  -106
  -134
  -171
  -218
  -278
  -352
  -441
  -546
  -668
  -808
  -966
  -1,143
  -1,338
  -1,551
  -1,783
  -2,032
  -2,298
  -2,581
  -2,881
  -3,197
  -3,528
  -3,876
  -4,239
  -4,617
  -5,011
  -5,422
  -5,848
  -6,292
Depreciation, amort., depletion, $m
  4
  5
  8
  12
  17
  23
  31
  40
  52
  66
  82
  100
  120
  143
  168
  195
  225
  257
  291
  327
  366
  406
  448
  492
  539
  587
  637
  689
  744
  800
Funds from operations, $m
  -67
  -80
  -98
  -122
  -154
  -196
  -248
  -312
  -389
  -480
  -586
  -708
  -846
  -1,000
  -1,170
  -1,356
  -1,558
  -1,775
  -2,007
  -2,254
  -2,516
  -2,791
  -3,080
  -3,383
  -3,700
  -4,030
  -4,374
  -4,732
  -5,105
  -5,492
Change in working capital, $m
  -5
  -7
  -10
  -14
  -18
  -23
  -29
  -36
  -43
  -51
  -59
  -68
  -77
  -85
  -94
  -103
  -111
  -119
  -127
  -135
  -143
  -151
  -158
  -165
  -173
  -180
  -188
  -195
  -203
  -211
Cash from operations, $m
  -62
  -73
  -88
  -108
  -136
  -172
  -218
  -276
  -345
  -429
  -527
  -640
  -769
  -915
  -1,076
  -1,253
  -1,447
  -1,656
  -1,880
  -2,119
  -2,372
  -2,640
  -2,922
  -3,218
  -3,527
  -3,850
  -4,187
  -4,537
  -4,902
  -5,281
Maintenance CAPEX, $m
  -2
  -4
  -5
  -8
  -12
  -17
  -23
  -31
  -40
  -52
  -66
  -82
  -100
  -120
  -143
  -168
  -195
  -225
  -257
  -291
  -327
  -366
  -406
  -448
  -492
  -539
  -587
  -637
  -689
  -744
New CAPEX, $m
  -6
  -10
  -13
  -18
  -24
  -31
  -39
  -48
  -58
  -68
  -79
  -91
  -102
  -114
  -126
  -137
  -148
  -160
  -170
  -181
  -191
  -201
  -211
  -221
  -231
  -241
  -251
  -261
  -272
  -282
Cash from investing activities, $m
  -8
  -14
  -18
  -26
  -36
  -48
  -62
  -79
  -98
  -120
  -145
  -173
  -202
  -234
  -269
  -305
  -343
  -385
  -427
  -472
  -518
  -567
  -617
  -669
  -723
  -780
  -838
  -898
  -961
  -1,026
Free cash flow, $m
  -71
  -86
  -107
  -135
  -172
  -220
  -280
  -354
  -444
  -549
  -672
  -813
  -971
  -1,149
  -1,345
  -1,559
  -1,791
  -2,040
  -2,307
  -2,591
  -2,891
  -3,207
  -3,539
  -3,887
  -4,251
  -4,630
  -5,024
  -5,435
  -5,862
  -6,307
Issuance/(repayment) of debt, $m
  10
  18
  25
  33
  44
  57
  72
  88
  106
  125
  145
  166
  187
  208
  229
  250
  271
  291
  311
  330
  349
  367
  386
  404
  422
  440
  458
  476
  495
  515
Issuance/(repurchase) of shares, $m
  73
  87
  109
  138
  176
  225
  286
  362
  452
  559
  684
  826
  987
  1,166
  1,363
  1,579
  1,813
  2,064
  2,333
  2,618
  2,920
  3,238
  3,571
  3,921
  4,285
  4,666
  5,062
  5,475
  5,903
  6,349
Cash from financing (excl. dividends), $m  
  83
  105
  134
  171
  220
  282
  358
  450
  558
  684
  829
  992
  1,174
  1,374
  1,592
  1,829
  2,084
  2,355
  2,644
  2,948
  3,269
  3,605
  3,957
  4,325
  4,707
  5,106
  5,520
  5,951
  6,398
  6,864
Total cash flow (excl. dividends), $m
  12
  19
  27
  36
  48
  62
  77
  95
  114
  135
  157
  179
  202
  225
  248
  271
  293
  315
  337
  357
  378
  398
  418
  437
  457
  476
  496
  516
  536
  557
Retained Cash Flow (-), $m
  -73
  -87
  -109
  -138
  -176
  -225
  -286
  -362
  -452
  -559
  -684
  -826
  -987
  -1,166
  -1,363
  -1,579
  -1,813
  -2,064
  -2,333
  -2,618
  -2,920
  -3,238
  -3,571
  -3,921
  -4,285
  -4,666
  -5,062
  -5,475
  -5,903
  -6,349
Prev. year cash balance distribution, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
  -61
  -68
  -82
  -101
  -128
  -163
  -209
  -267
  -338
  -424
  -527
  -647
  -785
  -941
  -1,115
  -1,308
  -1,520
  -1,749
  -1,996
  -2,261
  -2,542
  -2,840
  -3,154
  -3,483
  -3,829
  -4,190
  -4,567
  -4,959
  -5,367
  -5,792
Discount rate, %
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
  -58
  -62
  -71
  -83
  -99
  -118
  -141
  -167
  -194
  -223
  -250
  -276
  -298
  -316
  -327
  -332
  -331
  -322
  -307
  -287
  -263
  -236
  -207
  -177
  -149
  -122
  -98
  -77
  -59
  -44
Current shareholders' claim on cash, %
  15.5
  4.5
  1.5
  0.6
  0.2
  0.1
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0

T2 Biosystems, Inc. is an in vitro diagnostics company engaged in developing a technology platform offering an alternative to diagnostic methodologies. The Company's T2 Magnetic Resonance platform (T2MR) enables detection of pathogens, biomarkers and other abnormalities in a range of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as one colony forming unit per milliliter (CFU/mL). The Company's initial development efforts target sepsis, hemostasis and Lyme disease. T2MR is a miniaturized, magnetic resonance-based approach that measures how water molecules react in the presence of magnetic fields. Its platform detects a range of targets, including molecular targets, such as deoxyribonucleic acid (DNA), immunodiagnostics, such as proteins, and a range of hemostasis measurements. The Company offers T2Dx Instrument (T2Dx) and the T2Candida Panel.

FINANCIAL RATIOS  of  T2 Biosystems (TTOO)

Valuation Ratios
P/E Ratio -2.6
Price to Sales 35.8
Price to Book 3.7
Price to Tangible Book
Price to Cash Flow -3.1
Price to Free Cash Flow -2.8
Growth Rates
Sales Growth Rate 33.3%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate -37.5%
Cap. Spend. - 3 Yr. Gr. Rate 38%
Financial Strength
Quick Ratio 73
Current Ratio 0
LT Debt to Equity 102.6%
Total Debt to Equity 105.1%
Interest Coverage -17
Management Effectiveness
Return On Assets -58.8%
Ret/ On Assets - 3 Yr. Avg. -54.9%
Return On Total Capital -69.6%
Ret/ On T. Cap. - 3 Yr. Avg. -63.2%
Return On Equity -127.9%
Return On Equity - 3 Yr. Avg. -99.8%
Asset Turnover 0
Profitability Ratios
Gross Margin -75%
Gross Margin - 3 Yr. Avg. -13.9%
EBITDA Margin -1250%
EBITDA Margin - 3 Yr. Avg. -883.3%
Operating Margin -1275%
Oper. Margin - 3 Yr. Avg. -902.8%
Pre-Tax Margin -1375%
Pre-Tax Margin - 3 Yr. Avg. -958.3%
Net Profit Margin -1375%
Net Profit Margin - 3 Yr. Avg. -958.3%
Effective Tax Rate 0%
Eff/ Tax Rate - 3 Yr. Avg. 0%
Payout Ratio 0%

TTOO stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the TTOO stock intrinsic value calculation we used $4.666 million for the last fiscal year's total revenue generated by T2 Biosystems. The default revenue input number comes from 0001 income statement of T2 Biosystems. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our TTOO stock valuation model: a) initial revenue growth rate of 60% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for TTOO is calculated based on our internal credit rating of T2 Biosystems, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of T2 Biosystems.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of TTOO stock the variable cost ratio is equal to 380%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $40 million in the base year in the intrinsic value calculation for TTOO stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 21.6% for T2 Biosystems.

Corporate tax rate of 27% is the nominal tax rate for T2 Biosystems. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the TTOO stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for TTOO are equal to 236%.

Life of production assets of 4 years is the average useful life of capital assets used in T2 Biosystems operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for TTOO is equal to -176.5%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $1.34 million for T2 Biosystems - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 43.768 million for T2 Biosystems is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of T2 Biosystems at the current share price and the inputted number of shares is $0.2 billion.

RELATED COMPANIES Price Int.Val. Rating
BDX Becton Dickins 240.04 1,279.12  str.buy
ABT Abbott Laborat 70.73 72.84  hold
AXDX Accelerate Dia 14.44 0.58  str.sell
HAE Haemonetics 108.27 1.86  str.sell
BRKR Bruker 32.16 23.13  sell

COMPANY NEWS

▶ T2 Biosystems Reports Granting of Inducement Awards   [Nov-07-18 07:00AM  GlobeNewswire]
▶ T2 Biosystems: 3Q Earnings Snapshot   [Nov-01-18 05:30PM  Associated Press]
▶ T2 Biosystems Reports Granting of Inducement Awards   [Oct-05-18 07:00AM  GlobeNewswire]
▶ Here's Why T2 Biosystems Rose as Much as 16% Today   [Sep-26-18 04:56PM  Motley Fool]
▶ T2 Biosystems Reports Granting of Inducement Awards   [Aug-06-18 07:00AM  GlobeNewswire]
▶ T2 Biosystems: 2Q Earnings Snapshot   [Aug-02-18 05:39PM  Associated Press]
▶ T2 Biosystems to Participate in Two Upcoming Conferences   [Jul-24-18 07:00AM  GlobeNewswire]
▶ T2 Biosystems Reports Granting of Inducement Awards   [Jul-09-18 04:15PM  GlobeNewswire]
▶ T2 Biosystems Added to the Russell 3000® Index   [Jun-25-18 07:00AM  GlobeNewswire]
▶ How to Manage Risk in Biotech Stocks   [Jun-03-18 10:00AM  TheStreet.com]
▶ Here's Why T2 Biosystems, Inc. Rose Over 16% Today   [Jun-01-18 02:54PM  Motley Fool]
▶ T2 Biosystems: 1Q Earnings Snapshot   [May-08-18 06:19PM  Associated Press]
▶ T2 Biosystems Reports Granting of Inducement Awards   [May-03-18 08:00AM  GlobeNewswire]
▶ T2 Biosystems Reports Granting of Inducement Awards   [Apr-04-18 04:05PM  GlobeNewswire]
▶ T2 Biosystems Reports Granting of Inducement Award   [Mar-07-18 08:00AM  GlobeNewswire]
▶ T2 Biosystems Announces CFO Transition   [Feb-05-18 04:30PM  GlobeNewswire]
▶ Whats the Competitive Landscape for Accelerate Diagnostics?   [Jan-12-18 12:20PM  Market Realist]
▶ T2 Biosystems reports 3Q loss   [Nov-02-17 06:54PM  Associated Press]
▶ T2 Biosystems Announces Presentations at IDWeek 2017   [Sep-21-17 08:00AM  GlobeNewswire]
▶ T2 Biosystems Prices Secondary Offering   [Sep-15-17 10:25AM  24/7 Wall St.]
▶ With FDA filing, Lexington firm targets a scourge of hospitals: sepsis   [Sep-12-17 06:20PM  American City Business Journals]
▶ T2 Biosystems Announces 11 New Patents Granted in 2017   [Aug-30-17 08:00AM  GlobeNewswire]
▶ T2 Biosystems reports 2Q loss   [Aug-04-17 08:13PM  Associated Press]
▶ ETFs with exposure to T2 Biosystems, Inc. : July 13, 2017   [Jul-13-17 04:48PM  Capital Cube]

CONTACT US       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.